JP6438406B2 - 疎水性生理活性物質を送達するための組成物および方法 - Google Patents
疎水性生理活性物質を送達するための組成物および方法 Download PDFInfo
- Publication number
- JP6438406B2 JP6438406B2 JP2015540868A JP2015540868A JP6438406B2 JP 6438406 B2 JP6438406 B2 JP 6438406B2 JP 2015540868 A JP2015540868 A JP 2015540868A JP 2015540868 A JP2015540868 A JP 2015540868A JP 6438406 B2 JP6438406 B2 JP 6438406B2
- Authority
- JP
- Japan
- Prior art keywords
- agent
- delivery
- substance
- less
- hydrophobic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 170
- 230000002209 hydrophobic effect Effects 0.000 title claims description 143
- 239000012867 bioactive agent Substances 0.000 title claims description 80
- 238000000034 method Methods 0.000 title description 59
- 238000012384 transportation and delivery Methods 0.000 claims description 172
- 239000000126 substance Substances 0.000 claims description 142
- 125000002091 cationic group Chemical group 0.000 claims description 124
- 230000000975 bioactive effect Effects 0.000 claims description 95
- 229920002873 Polyethylenimine Polymers 0.000 claims description 82
- 229930012538 Paclitaxel Natural products 0.000 claims description 59
- 229960001592 paclitaxel Drugs 0.000 claims description 59
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 59
- 239000013543 active substance Substances 0.000 claims description 38
- 239000008365 aqueous carrier Substances 0.000 claims description 35
- 239000000463 material Substances 0.000 claims description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 16
- 229960002930 sirolimus Drugs 0.000 claims description 16
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 16
- 238000011200 topical administration Methods 0.000 claims description 12
- 239000003966 growth inhibitor Substances 0.000 claims description 9
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 8
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 8
- 229960005167 everolimus Drugs 0.000 claims description 8
- 230000007935 neutral effect Effects 0.000 claims description 8
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims description 8
- 229960005330 pimecrolimus Drugs 0.000 claims description 8
- 229960001967 tacrolimus Drugs 0.000 claims description 8
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 8
- YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical compound C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 claims description 8
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 claims description 8
- 229950009819 zotarolimus Drugs 0.000 claims description 8
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims description 6
- 239000004004 anti-anginal agent Substances 0.000 claims description 5
- 229940124345 antianginal agent Drugs 0.000 claims description 5
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 5
- 239000003146 anticoagulant agent Substances 0.000 claims description 5
- 229940127219 anticoagulant drug Drugs 0.000 claims description 5
- 239000003524 antilipemic agent Substances 0.000 claims description 5
- 239000002876 beta blocker Substances 0.000 claims description 5
- 229940097320 beta blocking agent Drugs 0.000 claims description 5
- 239000003246 corticosteroid Substances 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- 125000001302 tertiary amino group Chemical group 0.000 claims description 5
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 4
- 229940030600 antihypertensive agent Drugs 0.000 claims description 4
- 239000002220 antihypertensive agent Substances 0.000 claims description 4
- 239000000496 cardiotonic agent Substances 0.000 claims description 4
- 239000003149 muscarinic antagonist Substances 0.000 claims description 4
- 239000000730 antalgic agent Substances 0.000 claims description 3
- 229920001519 homopolymer Polymers 0.000 claims 1
- 229940124447 delivery agent Drugs 0.000 description 52
- 239000000725 suspension Substances 0.000 description 52
- 210000000056 organ Anatomy 0.000 description 46
- 210000001519 tissue Anatomy 0.000 description 40
- 239000007787 solid Substances 0.000 description 29
- 238000002156 mixing Methods 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- 239000003814 drug Substances 0.000 description 17
- 108010082117 matrigel Proteins 0.000 description 17
- 210000002889 endothelial cell Anatomy 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 150000004676 glycans Chemical class 0.000 description 15
- 229920001282 polysaccharide Polymers 0.000 description 15
- 239000005017 polysaccharide Substances 0.000 description 15
- -1 antibacterial Substances 0.000 description 12
- 238000004113 cell culture Methods 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 229940079593 drug Drugs 0.000 description 12
- 239000000654 additive Substances 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 150000001720 carbohydrates Chemical class 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 9
- 229920000669 heparin Polymers 0.000 description 9
- 230000009977 dual effect Effects 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 229960002897 heparin Drugs 0.000 description 8
- 150000003335 secondary amines Chemical class 0.000 description 8
- 230000000996 additive effect Effects 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 7
- 239000002953 phosphate buffered saline Substances 0.000 description 7
- 229920001983 poloxamer Polymers 0.000 description 7
- 230000032258 transport Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 241000124008 Mammalia Species 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000003125 aqueous solvent Substances 0.000 description 5
- 210000002808 connective tissue Anatomy 0.000 description 5
- 210000004351 coronary vessel Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229920002774 Maltodextrin Polymers 0.000 description 4
- 208000031481 Pathologic Constriction Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 210000000988 bone and bone Anatomy 0.000 description 4
- 239000007822 coupling agent Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 210000004789 organ system Anatomy 0.000 description 4
- 150000003141 primary amines Chemical class 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000036262 stenosis Effects 0.000 description 4
- 208000037804 stenosis Diseases 0.000 description 4
- 150000003512 tertiary amines Chemical class 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 229920006317 cationic polymer Polymers 0.000 description 3
- 239000006143 cell culture medium Substances 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000011026 diafiltration Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 210000003238 esophagus Anatomy 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 210000000232 gallbladder Anatomy 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000002324 mouth wash Substances 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008177 pharmaceutical agent Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 210000004560 pineal gland Anatomy 0.000 description 3
- 229960000502 poloxamer Drugs 0.000 description 3
- 229920000962 poly(amidoamine) Polymers 0.000 description 3
- 229920001601 polyetherimide Polymers 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 210000000278 spinal cord Anatomy 0.000 description 3
- 210000001032 spinal nerve Anatomy 0.000 description 3
- 238000012385 systemic delivery Methods 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- NRJAVPSFFCBXDT-HUESYALOSA-N 1,2-distearoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC NRJAVPSFFCBXDT-HUESYALOSA-N 0.000 description 2
- KWVJHCQQUFDPLU-YEUCEMRASA-N 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KWVJHCQQUFDPLU-YEUCEMRASA-N 0.000 description 2
- 206010051341 Bile duct stenosis Diseases 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 2
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 238000002679 ablation Methods 0.000 description 2
- 210000002534 adenoid Anatomy 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007975 buffered saline Substances 0.000 description 2
- 210000000748 cardiovascular system Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 239000002872 contrast media Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000000412 dendrimer Substances 0.000 description 2
- 229920000736 dendritic polymer Polymers 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 210000000188 diaphragm Anatomy 0.000 description 2
- 210000002249 digestive system Anatomy 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000000750 endocrine system Anatomy 0.000 description 2
- LZCLXQDLBQLTDK-UHFFFAOYSA-N ethyl 2-hydroxypropanoate Chemical compound CCOC(=O)C(C)O LZCLXQDLBQLTDK-UHFFFAOYSA-N 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 description 2
- 229960002603 iopromide Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- NFQBIAXADRDUGK-KWXKLSQISA-N n,n-dimethyl-2,3-bis[(9z,12z)-octadeca-9,12-dienoxy]propan-1-amine Chemical compound CCCCC\C=C/C\C=C/CCCCCCCCOCC(CN(C)C)OCCCCCCCC\C=C/C\C=C/CCCCC NFQBIAXADRDUGK-KWXKLSQISA-N 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 210000002990 parathyroid gland Anatomy 0.000 description 2
- 210000003899 penis Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 210000003800 pharynx Anatomy 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 210000003635 pituitary gland Anatomy 0.000 description 2
- 229920000765 poly(2-oxazolines) Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000004994 reproductive system Anatomy 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 210000001625 seminal vesicle Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- PBCZLFBEBARBBI-UHFFFAOYSA-N sulfabenzamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC(=O)C1=CC=CC=C1 PBCZLFBEBARBBI-UHFFFAOYSA-N 0.000 description 2
- 229960004730 sulfabenzamide Drugs 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 210000001550 testis Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001685 thyroid gland Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 210000000626 ureter Anatomy 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 210000001177 vas deferen Anatomy 0.000 description 2
- 201000010653 vesiculitis Diseases 0.000 description 2
- 230000002747 voluntary effect Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- CEMAWMOMDPGJMB-UHFFFAOYSA-N (+-)-Oxprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1OCC=C CEMAWMOMDPGJMB-UHFFFAOYSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- GUXHBMASAHGULD-SEYHBJAFSA-N (4s,4as,5as,6s,12ar)-7-chloro-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1([C@H]2O)=C(Cl)C=CC(O)=C1C(O)=C1[C@@H]2C[C@H]2[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]2(O)C1=O GUXHBMASAHGULD-SEYHBJAFSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- LVNGJLRDBYCPGB-LDLOPFEMSA-N (R)-1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-LDLOPFEMSA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- RKUNBYITZUJHSG-FXUDXRNXSA-N (S)-atropine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 description 1
- MWRBNPKJOOWZPW-NYVOMTAGSA-N 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine zwitterion Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-NYVOMTAGSA-N 0.000 description 1
- GJHKWLSRHNWTAN-UHFFFAOYSA-N 1-ethoxy-4-(4-pentylcyclohexyl)benzene Chemical compound C1CC(CCCCC)CCC1C1=CC=C(OCC)C=C1 GJHKWLSRHNWTAN-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- LDGWQMRUWMSZIU-LQDDAWAPSA-M 2,3-bis[(z)-octadec-9-enoxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCCOCC(C[N+](C)(C)C)OCCCCCCCC\C=C/CCCCCCCC LDGWQMRUWMSZIU-LQDDAWAPSA-M 0.000 description 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- GMQPELBCDCDDHW-UHFFFAOYSA-N 4-(3,9-diazaspiro[5.5]undecan-3-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1N1CCC2(CCNCC2)CC1 GMQPELBCDCDDHW-UHFFFAOYSA-N 0.000 description 1
- RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 208000023514 Barrett esophagus Diseases 0.000 description 1
- 208000023665 Barrett oesophagus Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- DJBNUMBKLMJRSA-UHFFFAOYSA-N Flecainide Chemical compound FC(F)(F)COC1=CC=C(OCC(F)(F)F)C(C(=O)NCC2NCCCC2)=C1 DJBNUMBKLMJRSA-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WDZVGELJXXEGPV-YIXHJXPBSA-N Guanabenz Chemical compound NC(N)=N\N=C\C1=C(Cl)C=CC=C1Cl WDZVGELJXXEGPV-YIXHJXPBSA-N 0.000 description 1
- 102100025255 Haptoglobin Human genes 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 206010023862 Laryngeal stenosis Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- 239000000026 Pentaerythritol tetranitrate Substances 0.000 description 1
- VBCPVIWPDJVHAN-UHFFFAOYSA-N Phenoxybenzamine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C[NH+](CCCl)C(C)COC1=CC=CC=C1 VBCPVIWPDJVHAN-UHFFFAOYSA-N 0.000 description 1
- 229920001212 Poly(beta amino esters) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 241000270934 Rana catesbeiana Species 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 239000004187 Spiramycin Substances 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- WKDDRNSBRWANNC-UHFFFAOYSA-N Thienamycin Natural products C1C(SCCN)=C(C(O)=O)N2C(=O)C(C(O)C)C21 WKDDRNSBRWANNC-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- HIHOWBSBBDRPDW-PTHRTHQKSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate Chemical compound C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HIHOWBSBBDRPDW-PTHRTHQKSA-N 0.000 description 1
- ISXSJGHXHUZXNF-LXZPIJOJSA-N [(3s,8s,9s,10r,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-yl] n-[2-(dimethylamino)ethyl]carbamate;hydrochloride Chemical compound Cl.C1C=C2C[C@@H](OC(=O)NCCN(C)C)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 ISXSJGHXHUZXNF-LXZPIJOJSA-N 0.000 description 1
- NYDLOCKCVISJKK-WRBBJXAJSA-N [3-(dimethylamino)-2-[(z)-octadec-9-enoyl]oxypropyl] (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC NYDLOCKCVISJKK-WRBBJXAJSA-N 0.000 description 1
- MWYNOTLRCUQCKD-UHFFFAOYSA-N [4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazin-1-yl]-(oxolan-2-yl)methanone;hydrate;hydrochloride Chemical compound O.Cl.N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 MWYNOTLRCUQCKD-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 229960002213 alprenolol Drugs 0.000 description 1
- PAZJSJFMUHDSTF-UHFFFAOYSA-N alprenolol Chemical compound CC(C)NCC(O)COC1=CC=CC=C1CC=C PAZJSJFMUHDSTF-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- IYIKLHRQXLHMJQ-UHFFFAOYSA-N amiodarone Chemical compound CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCCN(CC)CC)C(I)=C1 IYIKLHRQXLHMJQ-UHFFFAOYSA-N 0.000 description 1
- 229960005260 amiodarone Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- RNLQIBCLLYYYFJ-UHFFFAOYSA-N amrinone Chemical compound N1C(=O)C(N)=CC(C=2C=CN=CC=2)=C1 RNLQIBCLLYYYFJ-UHFFFAOYSA-N 0.000 description 1
- 229960002105 amrinone Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- HSNWZBCBUUSSQD-UHFFFAOYSA-N amyl nitrate Chemical compound CCCCCO[N+]([O-])=O HSNWZBCBUUSSQD-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- WOIIIUDZSOLAIW-NSHDSACASA-N azapropazone Chemical compound C1=C(C)C=C2N3C(=O)[C@H](CC=C)C(=O)N3C(N(C)C)=NC2=C1 WOIIIUDZSOLAIW-NSHDSACASA-N 0.000 description 1
- 229960001671 azapropazone Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- QZVNQOLPLYWLHQ-ZEQKJWHPSA-N benidipine Chemical compound C1([C@H]2C(=C(C)NC(C)=C2C(=O)OC)C(=O)O[C@H]2CN(CC=3C=CC=CC=3)CCC2)=CC=CC([N+]([O-])=O)=C1 QZVNQOLPLYWLHQ-ZEQKJWHPSA-N 0.000 description 1
- 229960004916 benidipine Drugs 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960000516 bezafibrate Drugs 0.000 description 1
- IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000002725 brachytherapy Methods 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- JQXXHWHPUNPDRT-YOPQJBRCSA-N chembl1332716 Chemical compound O([C@](C1=O)(C)O\C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)/C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CCN(C)CC1 JQXXHWHPUNPDRT-YOPQJBRCSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- DIOIOSKKIYDRIQ-UHFFFAOYSA-N ciprofloxacin hydrochloride Chemical compound Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 DIOIOSKKIYDRIQ-UHFFFAOYSA-N 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- WDQPAMHFFCXSNU-BGABXYSRSA-N clofazimine Chemical compound C12=CC=CC=C2N=C2C=C(NC=3C=CC(Cl)=CC=3)C(=N/C(C)C)/C=C2N1C1=CC=C(Cl)C=C1 WDQPAMHFFCXSNU-BGABXYSRSA-N 0.000 description 1
- 229960004287 clofazimine Drugs 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 229960002398 demeclocycline Drugs 0.000 description 1
- 230000002638 denervation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960002593 desoximetasone Drugs 0.000 description 1
- VWVSBHGCDBMOOT-IIEHVVJPSA-N desoximetasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@H](C(=O)CO)[C@@]1(C)C[C@@H]2O VWVSBHGCDBMOOT-IIEHVVJPSA-N 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- DOBMPNYZJYQDGZ-UHFFFAOYSA-N dicoumarol Chemical compound C1=CC=CC2=C1OC(=O)C(CC=1C(OC3=CC=CC=C3C=1O)=O)=C2O DOBMPNYZJYQDGZ-UHFFFAOYSA-N 0.000 description 1
- 229960001912 dicoumarol Drugs 0.000 description 1
- UMGXUWVIJIQANV-UHFFFAOYSA-M didecyl(dimethyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCC[N+](C)(C)CCCCCCCCCC UMGXUWVIJIQANV-UHFFFAOYSA-M 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- OGQYPPBGSLZBEG-UHFFFAOYSA-N dimethyl(dioctadecyl)azanium Chemical compound CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC OGQYPPBGSLZBEG-UHFFFAOYSA-N 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 229960002768 dipyridamole Drugs 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
- 229960001066 disopyramide Drugs 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- QYDYPVFESGNLHU-UHFFFAOYSA-N elaidic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCC(=O)OC QYDYPVFESGNLHU-UHFFFAOYSA-N 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 229960000972 enoximone Drugs 0.000 description 1
- ZJKNESGOIKRXQY-UHFFFAOYSA-N enoximone Chemical compound C1=CC(SC)=CC=C1C(=O)C1=C(C)NC(=O)N1 ZJKNESGOIKRXQY-UHFFFAOYSA-N 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 229960002001 ethionamide Drugs 0.000 description 1
- 229940116333 ethyl lactate Drugs 0.000 description 1
- 125000003916 ethylene diamine group Chemical group 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229960003580 felodipine Drugs 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229960003670 flecainide acetate Drugs 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960003973 fluocortolone Drugs 0.000 description 1
- GAKMQHDJQHZUTJ-ULHLPKEOSA-N fluocortolone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@@H](C)[C@H](C(=O)CO)[C@@]2(C)C[C@@H]1O GAKMQHDJQHZUTJ-ULHLPKEOSA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229960003050 guanabenz acetate Drugs 0.000 description 1
- ACGDKVXYNVEAGU-UHFFFAOYSA-N guanethidine Chemical compound NC(N)=NCCN1CCCCCCC1 ACGDKVXYNVEAGU-UHFFFAOYSA-N 0.000 description 1
- 229960003602 guanethidine Drugs 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 239000002628 heparin derivative Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000005661 hydrophobic surface Effects 0.000 description 1
- 229960003210 hyoscyamine Drugs 0.000 description 1
- 229930005342 hyoscyamine Natural products 0.000 description 1
- 229920000587 hyperbranched polymer Polymers 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960002182 imipenem Drugs 0.000 description 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N imipenem Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 210000001613 integumentary system Anatomy 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007925 intracardiac injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 229940113601 irrigation solution Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- MOYKHGMNXAOIAT-JGWLITMVSA-N isosorbide dinitrate Chemical compound [O-][N+](=O)O[C@H]1CO[C@@H]2[C@H](O[N+](=O)[O-])CO[C@@H]21 MOYKHGMNXAOIAT-JGWLITMVSA-N 0.000 description 1
- 229960000201 isosorbide dinitrate Drugs 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 229960003827 isosorbide mononitrate Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 229960003869 mepenzolate bromide Drugs 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- QYDYPVFESGNLHU-KHPPLWFESA-N methyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC QYDYPVFESGNLHU-KHPPLWFESA-N 0.000 description 1
- 229940073769 methyl oleate Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- IYJMSDVSVHDVGT-PEQKVOOWSA-N metildigoxin Chemical compound O1[C@H](C)[C@@H](OC)[C@@H](O)C[C@@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O IYJMSDVSVHDVGT-PEQKVOOWSA-N 0.000 description 1
- 229960003746 metildigoxin Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- ZAHQPTJLOCWVPG-UHFFFAOYSA-N mitoxantrone dihydrochloride Chemical compound Cl.Cl.O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO ZAHQPTJLOCWVPG-UHFFFAOYSA-N 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 description 1
- 229960004255 nadolol Drugs 0.000 description 1
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 1
- 229960000210 nalidixic acid Drugs 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960001783 nicardipine Drugs 0.000 description 1
- AIKVCUNQWYTVTO-UHFFFAOYSA-N nicardipine hydrochloride Chemical compound Cl.COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 AIKVCUNQWYTVTO-UHFFFAOYSA-N 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 229960004570 oxprenolol Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960000649 oxyphenbutazone Drugs 0.000 description 1
- HFHZKZSRXITVMK-UHFFFAOYSA-N oxyphenbutazone Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=C(O)C=C1 HFHZKZSRXITVMK-UHFFFAOYSA-N 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960004321 pentaerithrityl tetranitrate Drugs 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 229960000280 phenindione Drugs 0.000 description 1
- NFBAXHOPROOJAW-UHFFFAOYSA-N phenindione Chemical compound O=C1C2=CC=CC=C2C(=O)C1C1=CC=CC=C1 NFBAXHOPROOJAW-UHFFFAOYSA-N 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 229960002508 pindolol Drugs 0.000 description 1
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000333 poly(propyleneimine) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- WFXFYZULCQKPIP-UHFFFAOYSA-N prazosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 WFXFYZULCQKPIP-UHFFFAOYSA-N 0.000 description 1
- FYPMFJGVHOHGLL-UHFFFAOYSA-N probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 description 1
- 229960003912 probucol Drugs 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- DERJYEZSLHIUKF-UHFFFAOYSA-N procarbazine hydrochloride Chemical compound Cl.CNNCC1=CC=C(C(=O)NC(C)C)C=C1 DERJYEZSLHIUKF-UHFFFAOYSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 150000003148 prolines Chemical class 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 1
- 238000011471 prostatectomy Methods 0.000 description 1
- 229940070353 protamines Drugs 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 229960004482 quinidine sulfate Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002254 renal artery Anatomy 0.000 description 1
- 230000008660 renal denervation Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 210000005000 reproductive tract Anatomy 0.000 description 1
- QEVHRUUCFGRFIF-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C(C5=CC=C(OC)C=C5N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 QEVHRUUCFGRFIF-MDEJGZGSSA-N 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007632 sclerotherapy Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 229960001294 spiramycin Drugs 0.000 description 1
- 235000019372 spiramycin Nutrition 0.000 description 1
- 229930191512 spiramycin Natural products 0.000 description 1
- 229910002076 stabilized zirconia Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- SKIVFJLNDNKQPD-UHFFFAOYSA-N sulfacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 SKIVFJLNDNKQPD-UHFFFAOYSA-N 0.000 description 1
- 229960002673 sulfacetamide Drugs 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 229960000654 sulfafurazole Drugs 0.000 description 1
- 229960002597 sulfamerazine Drugs 0.000 description 1
- QPPBRPIAZZHUNT-UHFFFAOYSA-N sulfamerazine Chemical compound CC1=CC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 QPPBRPIAZZHUNT-UHFFFAOYSA-N 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- 229960002211 sulfapyridine Drugs 0.000 description 1
- GECHUMIMRBOMGK-UHFFFAOYSA-N sulfapyridine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CC=CC=N1 GECHUMIMRBOMGK-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 229960001693 terazosin Drugs 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229920000428 triblock copolymer Polymers 0.000 description 1
- 229960001032 trihexyphenidyl Drugs 0.000 description 1
- QDWJJTJNXAKQKD-UHFFFAOYSA-N trihexyphenidyl hydrochloride Chemical compound Cl.C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 QDWJJTJNXAKQKD-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
- 108010027843 zonulin Proteins 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/63—Crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
Description
特定の実施形態では、例えば以下が提供される:
(項目1)
疎水性生理活性物質を局所投与するための送達組成物であって、
カチオン性送達物質と;
治療有効量の前記疎水性生理活性物質と;
薬学的に許容される水性担体と;
を含む、組成物。
(項目2)
前記カチオン性送達物質がポリエチレンイミン(PEI)を含む、項目1および項目3〜19のいずれか一項に記載の組成物。
(項目3)
前記カチオン性送達物質が分岐鎖PEIを含む、項目1〜2および項目4〜19のいずれか一項に記載の組成物。
(項目4)
前記分岐鎖PEIの分子量が約25kD以上且つ約5000kD以下である、項目1〜3および項目5〜19のいずれか一項に記載の組成物。
(項目5)
前記分岐鎖PEIの分子量が約100kD以上且つ約3000kD以下である、項目1〜4および項目6〜19のいずれか一項に記載の組成物。
(項目6)
前記分岐鎖PEIの分子量が約500kD以上且つ約1000kD以下である、項目1〜5および項目7〜19のいずれか一項に記載の組成物。
(項目7)
分岐鎖PEIの第一級アミン:第二級アミン:第三級アミンの比が約1:3:1〜約1:1:1である、項目1〜6および項目8〜19のいずれか一項に記載の組成物。
(項目8)
分岐鎖PEIの第一級アミン:第二級アミン:第三級アミンの比が約1:2:1〜約1:1:1である、項目1〜7および項目9〜19のいずれか一項に記載の組成物。
(項目9)
カチオン性送達物質:疎水性生理活性物質を約1:1以上且つ約1:25以下の比で含む、項目1〜8および項目10〜19のいずれか一項に記載の組成物。
(項目10)
カチオン性送達物質:疎水性生理活性物質を約1:2以上且つ約1:20以下の比で含む、項目1〜9および項目11〜19のいずれか一項に記載の組成物。
(項目11)
カチオン性送達物質:疎水性生理活性物質を約1:5以上且つ約1:10以下の比で含む、項目1〜10および項目12〜19のいずれか一項に記載の組成物。
(項目12)
約1mg/ml以上、且つ約25mg/ml以下のカチオン性送達物質を含む、項目1〜11および項目13〜19のいずれか一項に記載の組成物。
(項目13)
約5mg/ml以上、且つ約125mg/ml以下の疎水性生理活性物質を含む、項目1〜12および項目14〜19のいずれか一項に記載の組成物。
(項目14)
前記水性担体が水および緩衝生理食塩水から選択される、項目1〜13および項目15〜19のいずれか一項に記載の組成物。
(項目15)
pHが5〜9である、項目1〜14および項目16〜19のいずれか一項に記載の組成物。
(項目16)
pHが6〜8である、項目1〜15および項目17〜19のいずれか一項に記載の組成物。
(項目17)
pHが7〜8である、項目1〜16および項目18〜19のいずれか一項に記載の組成物。
(項目18)
前記疎水性生理活性物質が、増殖抑制剤、鎮痛剤、抗炎症剤、抗不整脈剤、抗菌剤、抗凝固剤、降圧剤、抗ムスカリン剤、抗腫瘍剤、β遮断薬、強心剤、コルチコステロイド、脂質降下剤、抗狭心症剤、およびこれらの組み合わせから選択される、項目1〜17および項目19のいずれか一項に記載の組成物。
(項目19)
前記疎水性生理活性物質が、パクリタキセル、シロリムス、エベロリムス、biolimus A9、ゾタロリムス、タクロリムス、およびピメクロリムス、ならびにこれらの混合物から選択される増殖抑制剤である、項目1〜18のいずれか一項に記載の組成物。
(項目20)
項目1〜19のいずれか一項に記載の送達組成物の製造方法であって、
(A)前記疎水性生理活性物質を前記水性担体と混合して生理活性物質懸濁液を形成する工程と;
(B)前記カチオン性送達物質を前記生理活性物質懸濁液に添加して前記送達組成物を形成する工程と;
を含む、方法。
(項目21)
前記疎水性生理活性物質を前記水性担体と混合して前記生理活性物質懸濁液を形成する前に、前記疎水性生理活性物質を結晶化する工程を含む、項目20および項目22〜23のいずれか一項に記載の方法。
(項目22)
前記カチオン性送達物質を前記生理活性物質懸濁液に添加する前に、前記カチオン性送達物質を水溶液と混合してカチオン性送達物質溶液を形成する工程を含む、項目20〜21および項目23のいずれか一項に記載の方法。
(項目23)
前記カチオン性送達物質を前記生理活性物質懸濁液に添加する前に、前記カチオン性送達物質溶液のpHをpH5〜9に調節する工程を含む、項目20〜22のいずれか一項に記載の方法。
(項目24)
項目1〜19のいずれか一項に記載の送達組成物の製造方法であって、
(A)前記疎水性生理活性物質を前記カチオン性送達物質と混合して生理活性物質の混合物を形成する工程と;
(B)前記生理活性物質の混合物を前記水性担体と混合して前記送達組成物を形成する工程と;
を含む、方法。
(項目25)
前記生理活性物質の混合物を前記水性担体と混合する前に、前記生理活性物質の混合物を結晶化する工程を含む、項目24に記載の方法。
(項目26)
(A)治療有効量の疎水性生理活性物質と;
(B)カチオン性送達物質と;
を含む、キット。
(項目27)
固体の疎水性生理活性物質を含む、項目26および項目28〜45のいずれか一項
に記載のキット。
(項目28)
水溶液中に疎水性生理活性物質を含む、項目26〜27および項目29〜45のいずれか一項に記載のキット。
(項目29)
非晶質疎水性生理活性物質を含む、項目26〜28および項目30〜45のいずれか一項に記載のキット。
(項目30)
結晶性疎水性生理活性物質を含む、項目26〜29および項目31〜45のいずれか一項に記載のキット。
(項目31)
純粋なまたは未希釈の送達物質を含む、項目26〜30および項目32〜45のいずれか一項に記載のキット。
(項目32)
非晶質カチオン性送達物質を含む、項目26〜31および項目33〜45のいずれか一項に記載のキット。
(項目33)
結晶性カチオン性送達物質を含む、項目26〜32および項目34〜45のいずれか一項に記載のキット。
(項目34)
水溶液中にカチオン性送達物質を含む、項目26〜33および項目35〜45のいずれか一項に記載のキット。
(項目35)
薬学的に許容される水性担体をさらに含む、項目26〜34および項目36〜45のいずれか一項に記載のキット。
(項目36)
使用説明書をさらに含む、項目26〜35および項目37〜45のいずれか一項に記載のキット。
(項目37)
純粋なまたは未希釈の送達物質と;
結晶性疎水性生理活性物質と;
前記結晶性疎水性生理活性物質を薬学的に許容される水性担体で再懸濁して生理活性物質懸濁液を形成し、前記純粋なまたは未希釈の送達物質を前記生理活性物質懸濁液に添加するための使用説明書と;
を含む、項目26〜36および項目38〜45のいずれか一項に記載のキット。
(項目38)
前記薬学的に許容される水性担体をさらに含む、項目26〜37および項目39〜45のいずれか一項に記載のキット。
(項目39)
純粋なまたは未希釈の送達物質と;
前記治療有効量の疎水性生理活性物質を含む懸濁液と;
前記純粋なまたは未希釈の送達物質を前記疎水性生理活性物質の懸濁液と混合するための使用説明書と;
を含む、項目26〜38および項目40〜45のいずれか一項に記載のキット。
(項目40)
固体の疎水性生理活性物質と純粋なまたは未希釈の送達物質との混合物であって、疎水性生理活性物質:カチオン性送達物質の比が約1:5未満である混合物と、
前記混合物を薬学的に許容される水性担体で再溶解/再懸濁するための使用説明書と、を含む、項目26〜39および項目41〜45のいずれか一項に記載のキット。
(項目41)
薬学的に許容される水性担体中に前記固体の疎水性生理活性物質と純粋なまたは未希釈の送達物質とを含む懸濁液であって、前記懸濁液のpHが約5〜約9である懸濁液、
を含む、項目26〜40および項目42〜45のいずれか一項に記載のキット。
(項目42)
前記疎水性生理活性物質が、増殖抑制剤、鎮痛剤、抗炎症剤、抗不整脈剤、抗菌剤、抗凝固剤、降圧剤、抗ムスカリン剤、抗腫瘍剤、β遮断薬、強心剤、コルチコステロイド、脂質降下剤、抗狭心症剤、およびこれらの組み合わせから選択される、項目26〜41および項目43〜45のいずれか一項に記載のキット。
(項目43)
前記疎水性生理活性物質が、パクリタキセル、シロリムス(ラパマイシン)、エベロリムス、biolimus A9、ゾタロリムス、タクロリムス、およびピメクロリムス、ならびにこれらの混合物から選択される増殖抑制剤を含む、項目26〜42および項目44〜45のいずれか一項に記載のキット。
(項目44)
前記カチオン性送達物質がPEIを含む、項目26〜43および項目45のいずれか一項に記載のキット。
(項目45)
前記カチオン性送達物質が分岐鎖PEIを含む、項目26〜44のいずれか一項に記載のキット。
(項目46)
治療有効量または予防有効量の疎水性生理活性物質を患者の組織または臓器に局所投与するための方法であって、
項目1〜19のいずれか一項に記載の組成物を製造する工程と;
前記組成物を前記患者の組織または臓器に適用する工程と;
を含む、方法。
(項目47)
前記患者が哺乳動物である、項目46および項目48〜62のいずれか一項に記載の方法。
(項目48)
前記患者がヒトである、項目46〜47および項目49〜62のいずれか一項に記載の方法。
(項目49)
前記組織が固形組織を含む、項目46〜48および項目50〜62のいずれか一項に記載の方法。
(項目50)
前記組織が、結合組織、筋肉組織、神経組織、上皮組織、またはこれらの組み合わせから選択される、項目46〜49および項目51〜62のいずれか一項に記載の方法。
(項目51)
前記臓器が、心血管系、消化器系、内分泌系、排出系、免疫系、外皮系、筋系、神経系、生殖系、呼吸器系、骨格系、またはこれらの組み合わせの臓器から選択される、項目46〜50および項目52〜62のいずれか一項に記載の方法。
(項目52)
前記心血管系の臓器が、心臓、血管およびこれらの組み合わせから選択される、項目46〜51および項目53〜62のいずれか一項に記載の方法。
(項目53)
前記消化器系の臓器が、唾液腺、食道、胃、肝臓、胆嚢、膵臓、腸、結腸、直腸および肛門から選択される、項目46〜52および項目54〜62のいずれか一項に記載の方法。
(項目54)
前記内分泌系の臓器が、視床下部、下垂体、松果腺、甲状腺、副甲状腺および副腎から
選択される、項目46〜53および項目55〜62のいずれか一項に記載の方法。
(項目55)
前記排出系の臓器が、腎臓、尿管、膀胱および尿道から選択される、項目46〜54および項目56〜62のいずれか一項に記載の方法。
(項目56)
前記免疫系の臓器が、扁桃腺、アデノイド、胸腺および脾臓から選択される、項目46〜55および項目57〜62のいずれか一項に記載の方法。
(項目57)
前記外皮系の臓器が、皮膚、毛髪および爪から選択される、項目46〜56および項目58〜62のいずれか一項に記載の方法。
(項目58)
前記筋系の臓器が、随意筋および不随意筋から選択される、項目46〜57および項目59〜62のいずれか一項に記載の方法。
(項目59)
前記神経系の臓器が、脳、脊髄および神経から選択される、項目46〜58および項目60〜62のいずれか一項に記載の方法。
(項目60)
前記生殖系の臓器が、卵巣、卵管、子宮、膣、乳腺、精巣、精管、精嚢、前立腺および陰茎から選択される、項目46〜59および項目61〜62のいずれか一項に記載の方法。
(項目61)
前記呼吸器系の臓器が、咽頭、喉頭、気管、気管支、肺および横隔膜から選択される、項目46〜60および項目62のいずれか一項に記載の方法。
(項目62)
前記骨格系の臓器が、骨、軟骨、靭帯および腱から選択される、項目46〜61のいずれか一項に記載の方法。
一実施形態では、送達組成物は1種以上の疎水性生理活性物質を含む。一般に、「疎水性生理活性物質」という用語は、水に対する溶解度が25℃および中性pHで約100μg/mL未満、25℃および中性pHで約10μg/mL未満、または25℃および中性pHで約5μg/ml未満の生理活性物質を指す。一実施形態では、疎水性生理活性物質は結晶性である。一般に、「結晶性」という用語は、分子が規則的に配列した繰り返しパターンで充填されている「長距離分子秩序」を有する熱力学的に安定な固体状の生理活性物質を指す。別の実施形態では、疎水性生理活性物質は非晶質である。「非晶質」という用語は、分子が「長距離分子秩序」を有しておらず、不規則に配置されているまたは液体に典型的な「短距離分子秩序」しか保たない、固体状の生理活性物質を指す。一般に、結晶形の生理活性物質の方が非晶形の同生理活性物質よりも純度が高く、安定性が高い傾向がある。さらに、結晶形の生理活性物質の方が非晶形よりも溶解性が高い傾向がある。当業者には、生理活性物質が結晶形であるかまたは非晶形であるかを判定する方法、例えば、X線回折などが分かる。
一実施形態では、送達組成物は、疎水性生理活性物質とカチオン性送達物質とを含む。理論に拘束されることを望むものではないが、カチオン性送達物質により付与される電荷により、組成物は、患者の組織または臓器上または内に存在する脂質二重層と結合している負電荷および/または極性基、または細胞外マトリックス(例えば、コラーゲン、フィブロネクチン、ラミニン等)と結合している荷電基および/または極性基に静電気的に引き付けられると考えられている。そのため、局所投与用の組成物中で生理活性物質、特に、疎水性生理活性物質をカチオン性送達物質と混合すると、投与部位の近傍に疎水性生理活性物質を滞留させることに役立つ。また、カチオン性送達物質により組織透過性が向上し、それにより標的組織および/または臓器による生理活性物質の取り込みが増加し得ることも考えられる。
他の実施形態では、本発明の送達組成物は、希釈剤、賦形剤、アジュバント、乳化剤、緩衝剤、安定剤および保存剤等のその他の成分を1種以上含むことができる。一実施形態では、送達組成物は1種以上の造影剤、例えば、ヨウ素化造影剤を含む。
一実施形態では、送達組成物は、薬学的に許容される水性担体中に疎水性生理活性物質とカチオン性送達物質とを含む。本明細書で使用する場合、「薬学的に許容される担体」とは、生物に著しい刺激を引き起こさず、投与された組成物の生理活性および特性を阻害しない担体または希釈剤を指す。一実施形態では、水性担体としては水または緩衝生理食塩水が挙げられる。より詳細な実施形態では、水性担体としては重水素減少水(DDW)が挙げられる。一実施形態では、疎水性生理活性物質および/またはカチオン性送達物質を水に懸濁させる。一実施形態では、担体は生物適合性溶媒を少量(例えば、約20%未満、約15%未満、約10%未満、約9%未満、約8%未満、約7%未満、約6%未満、約5%未満、約4%未満、約3%未満、約2%未満、または約1%未満)含む。本明細書で使用する場合、「生物適合性溶媒」という用語は、無毒と見なされ、担体中に含まれる量で免疫反応を誘発しない溶媒を指す。生物適合性溶媒の例としては、エタノール、乳酸エチル、アセトン、ジメチルスルホキシド(DMSO)、およびこれらの組み合わせが挙げられるが、これらに限定されるものではない。一実施形態では、疎水性生理活性物質をコーティングされた治療剤として水に懸濁させる。一実施形態では、疎水性生理活性物質をカチオン性送達物質と結合させるために、混合工程または撹拌工程を行うことができる。幾つかの実施形態では、カチオン性送達物質は、粒子状の疎水性生理活性物質を包囲および/または内包し、コーティングされた生理活性物質粒子を形成する。
一実施形態では、本発明は本明細書に記載の送達組成物の製造方法に関する。一実施形態では、送達組成物は、水性担体中に疎水性生理活性物質とカチオン性送達物質とを含む。より詳細な実施形態では、カチオン性送達物質としてはPEIが挙げられる。別の実施形態では、カチオン性送達物質としては分岐鎖PEIが挙げられる。特定の実施形態では、疎水性生理活性物質は、パクリタキセル、シロリムス(ラパマイシン)、エベロリムス、biolimus A9、ゾタロリムス、タクロリムス、およびピメクロリムス、ならびにこれらの混合物である。
本発明の別の実施形態はキットおよび製品に関する。特に、本発明は、本明細書に記載の送達組成物を含むキットまたはパッケージを提供する。一実施形態では、本発明は、送達組成物の成分の1種以上を含むキットを提供する。本明細書で使用する場合、「送達組成物の成分」は、送達組成物中に含まれる、1種以上の疎水性生理活性物質、1種以上のカチオン性送達物質、1種以上の薬学的に許容される水性担体、ならびに他の任意の添加剤、希釈剤、賦形剤、アジュバント、乳化剤、緩衝剤、安定剤、保存剤を指すことができる。一実施形態では、キットは、1種以上の疎水性生理活性物質および1種以上のカチオン性送達物質、ならびに疎水性生理活性物質とカチオン性送達物質を混合して局所投与に好適な送達組成物を形成するための使用説明書を含む。一実施形態では、カチオン性送達物質としてはPEIが挙げられる。別の実施形態では、カチオン性送達物質としては分岐鎖PEIが挙げられる。特定の実施形態では、疎水性生理活性物質はパクリタキセル、シロリムス(ラパマイシン)、エベロリムス、biolimus A9、ゾタロリムス、タクロリムス、およびピメクロリムス、ならびにこれらの混合物である。
本発明はまた、治療有効量の疎水性生理活性物質を患者の組織、臓器または臓器系に送達する方法も提供する。より詳細な実施形態では、本発明は、治療有効量の疎水性生理活性物質を患者の固形組織または臓器に局所送達する方法を提供する。理論に拘束されることを望むものではないが、疎水性生理活性物質をPEIなどのカチオン性送達物質と混合すると、組織または臓器表面への生理活性物質の接着が改善され、これにより、それが適用される組織または臓器による疎水性生理活性物質のバイオアベイラビリティおよび取り込みが増加すると考えらえる。カチオン性送達物質はまた、細胞間の結合の一部を破壊して、透過性を向上させ、生理活性物質を組織または臓器内に浸透させることもできる。治療性能を改善するカチオン性送達物質の能力は、疎水性生理活性物質と組み合わせて使用される場合、最も顕著であるように見受けられる。より溶解性が高い親水性生理活性物質は、生理液により組織または臓器の表面から、より洗い流され易いと考えられる。
内皮細胞を播種したまたは播種していない表面へのパクリタキセルの送達について、未処理の24ウェルポリスチレン組織培養プレート(TCPS);Matrigel(商標)でコーティングされた24ウェル細胞培養プレート(BD Matrigel(商標)Matrix Thin−Layer細胞;Becton Dickinson Biosciences,Franklin Lakes,NJから入手可能)、またはヘパリン含有HP01コーティングまたはコラーゲン含有CL01コーティング(SurModics,Eden Prarie,MNから入手可能)で処理した24ウェル細胞培養プレートを使用して、in−vitroで試験を行った。ヒト冠状動脈内皮細胞(HCAEC、Lonza,Walkersville,MDから入手可能)をEGM(商標)−2MV増殖培地(Lonza,Walkersville、MDから入手可能)中で培養した。パクリタキセル輸送試験の1日前に、細胞を様々な培養プレートに1ウェル当たり培地0.5mL中の細胞数が50,000個となるように播種した。パクリタキセル(LC Laboratories,Woburn,MAから入手可能)の水懸濁液は、パクリタキセルが55.2mg/mlとなり、4.8mg/mlのPEI(Polysciences,Warrington,PAから入手可能,MW=750kDa)を含むようにまたは含まないように調製した。懸濁液を短時間音波処理した。得られた懸濁液(6.7μL)を細胞培地(100μL)に添加して細胞培養プレートに入れ、3分間インキュベートした。100μLの培地(100μL)を有するが細胞を播種していない異なる24ウェルプレートにも懸濁液を添加した。インキュベート後、プレートをリン酸緩衝生理食塩水(1ウェル当たり500μL)で3回洗浄し、終夜乾燥させた。接着の結果としてプレート内に残存するパクリタキセルをメタノール250μLに溶解し、HPLCで定量した。輸送されたパクリタキセルの量を図1に示す。
内皮細胞を播種したまたは播種していない表面へのパクリタキセルの送達について、Matrigel(商標)でコーティングされた96ウェル細胞培養プレート(BD Matrigel(商標)Matrix Thin−Layer細胞、Becton Dickinson Biosciences,Franklin Lakes,NJから入手可能)を使用してin−vitroで試験を行った。ヒト冠状動脈内皮細胞(HCAEC、Lonza,Walkersville,MDから入手可能)をEGM(商標)−2MV増殖培地(Lonza,Walkersville,MDから入手可能)中で培養した。パクリタキセル輸送試験の1日前に、細胞を様々な培養プレートに1ウェル当たり培地0.2mL中の細胞数が20,000個となるように播種した。パクリタキセル(LC Laboratories,Woburn,MA)の水懸濁液は、パクリタキセルが11mg/mlとなり、1mg/mlのPEI(Polysciences,Warrington,PAから入手可能;MW=750kDa)を含むようにまたは含まないように調製した。使用前に懸濁液を短時間音波処理した。得られた懸濁液(5μL)を細胞培地0.1mLに添加して、細胞培養プレートに入れ、3分間インキュベートした。また、培地0.1mLを有するが細胞を播種していない、Matrigel(商標)でコーティングされたプレートにも懸濁液を添加した。インキュベート後、プレートをリン酸緩衝生理食塩水(1ウェル当たり0.2mL)で3回洗浄し、終夜乾燥させた。接着の結果としてプレート内に残存するパクリタキセルをメタノール/0.1%酢酸250μLに溶解し、HPLCで定量した。輸送されたパクリタキセルの量を図2に示す。
内皮細胞および組織へのパクリタキセルの送達について、Matrigel(商標)でコーティングされた細胞培養プレート上で増殖した細胞を用いてin−vitroで試験を行った。ヒト冠状動脈内皮細胞(HCAEC、Lonza,Walkersville,MD)をEGM(商標)−2MV増殖培地(Lonza,Walkersville,MD)中で培養した。パクリタキセル輸送試験の1日前に、細胞を96ウェルBD Matrigel(商標)Matrix Thin−Layer細胞培養プレートに1ウェル当たり培地0.2mL中の細胞数が20,000個となるように播種した。パクリタキセル(LC Laboratories,Woburn,MA)の水懸濁液は、パクリタキセルが11mg/mlとなり、PEI(Polysciences,Warrington,PA;MW=750kDa)またはPAMAM、エチレンジアミンコア、第4世代、デンドリマー(Sigma,Milwaukee,WI;14,214Da)が0.96mg/mL(w/w比92:8)となるように、またはイオプロミドが11mg/ml(IOPR、w/w比1:1)となるように調製した。使用前に懸濁液を短時間音波処理した。得られた懸濁液(5μL)を細胞培養プレートに添加して3分間または10分間インキュベートした。また、培地を有するが細胞を有していない、Matrigel(商標)でコーティングされたプレートにも懸濁液を添加した。インキュベート後、プレートをリン酸緩衝生理食塩水(1ウェル当たり200μL)で3回洗浄し、終夜乾燥させた。プレート内に残存するパクリタキセルをメタノール(250μL)に溶解し、HPLCで定量した。輸送されたパクリタキセルの量を図3に示す。
様々な濃度のヘパリンの存在下での、内皮細胞を播種したまたは播種していない表面へのパクリタキセルの接着について、Matrigel(商標)でコーティングされた96ウェル細胞培養プレート(BD Matrigeltm Matrix Thin−Layer細胞、BD Biosciences,San Jose,CA)を使用してin−vitroで試験を行った。ヒト冠状動脈内皮細胞(HCAEC、Lonza,Walkersville,MD)をEGM(商標)−2MV増殖培地(Lonza,Walkersville,MD)中で培養した。パクリタキセル輸送試験の1日前に、細胞を様々な培養プレートに1ウェル当たり培地0.2mL中の細胞数が20,000個となるように播種した。パクリタキセルを添加する前に、ヘパリン(ナトリウム塩、Celsus,Cincinnati,OH)を増殖培地に、25mg/ml、5mg/ml、1mg/ml、0.2mg/ml、0.04mg/ml、0.008mg/mlおよび0.0016mg/mlの濃度になるように溶解し、細胞培養プレート内の培地をヘパリン含有培地で置換した。パクリタキセル(LC Laboratories,Woburn,MA)の水懸濁液は、パクリタキセルが11mg/mlとなり、1mg/mlのPEI(Polysciences,Warrington,PA)を有するようにまたは有しないように調製した。使用前に懸濁液を短時間音波処理した。懸濁液5μLを、細胞を有するプレート内の増殖培地と、細胞を有していないプレート内の増殖培地に添加して4分間インキュベートした。インキュベート後、プレートをリン酸緩衝生理食塩水(1ウェル当たり0.2mL)で3回洗浄し、終夜乾燥させた。接着の結果としてプレート内に残存するパクリタキセルをメタノール(60μL)に溶解し、HPLCで定量した。PEIと様々なヘパリン濃度とを有する場合と、それらを有していない場合の、輸送されたパクリタキセルの量を図4および図5に示す。
内皮細胞を播種したまたは播種していない表面へのパクリタキセルの接着について、Matrigel(商標)でコーティングされた96ウェル細胞培養プレート(BD Matrigel(商標)Matrix Thin−Layer細胞)を使用してin−vitroで試験を行った。ヒト冠状動脈内皮細胞(HCAEC、Lonza,Walkersville,MD)をEGM(商標)−2MV増殖培地(Lonza)中で培養した。パクリタキセル輸送試験の1日前に、細胞を培養プレートの7〜12列のウェルに、1ウェル当たり培地0.2mL中の細胞数が20,000個となるように播種した。24時間インキュベートした後、全てのウェル内の培地を新しい培地100ulで置換した。パクリタキセル(LC Labs、「音波処理したもの」)を分岐鎖PEI水溶液に懸濁させた懸濁液は、パクリタキセルが11mg/mlおよびPEIが1mg/mlとなるように調製した。異なる分子量を有する分岐鎖PEI、即ち、polysciences製とSigma製の共に750kDaのものと、Sigma製の70kDaおよび25kDaのものと、polysciences製の1200Daおよび600Daのものとを使用した。使用前に、全ての懸濁液を短時間音波処理し、確実に、全ての成分が十分に分散するようにした。1製剤当たり12ウェルで(6ウェルではmatrigel上にHCAECを播種し、6ウェルではmatrigel上にHCAECを播種しなかった):懸濁液5μLを細胞培地0.1mLに添加した。プレートを3分間インキュベートし、その間、懸濁液を沈降させた。インキュベート後、プレートをリン酸緩衝生理食塩水(1ウェル当たり0.2mL)で3回洗浄し、終夜乾燥させた。接着の結果としてプレート内に残存するパクリタキセルをメタノール/0.1%酢酸250μLに溶解し、HPLCで定量した。輸送されたパクリタキセルの量を図6に示す。
Claims (9)
- 疎水性生理活性物質を局所投与するための水性送達組成物であって、
カチオン性送達物質と;
治療有効量の前記疎水性生理活性物質と;
薬学的に許容される水性担体と;
を含み、前記カチオン性送達物質が分岐鎖ポリエチレンイミン(PEI)ホモポリマーを含む、組成物。 - 前記分岐鎖PEIの分子量が約25kD以上且つ約5000kD以下である、請求項1に記載の組成物。
- 前記分岐鎖PEIの第一級アミノ基:第二級アミノ基:第三級アミノ基の比が約1:3:1〜約1:1:1(モル比)である、請求項1または2に記載の組成物。
- 約5mg/ml以上、且つ約125mg/ml以下の疎水性生理活性物質を含む、請求項1〜3のいずれか一項に記載の組成物。
- 約1mg/ml以上、且つ約25mg/ml以下のカチオン性送達物質を含む、請求項1〜4のいずれか一項に記載の組成物。
- pHが5〜9である、請求項1〜5のいずれか一項に記載の組成物。
- 前記疎水性生理活性物質が、増殖抑制剤、鎮痛剤、抗炎症剤、抗不整脈剤、抗菌剤、抗凝固剤、降圧剤、抗ムスカリン剤、抗腫瘍剤、β遮断薬、強心剤、コルチコステロイド、脂質降下剤、抗狭心症剤、およびこれらの組み合わせから選択される、請求項1〜6のいずれか一項に記載の組成物。
- 前記疎水性生理活性物質が、パクリタキセル、シロリムス、エベロリムス、biolimus A9、ゾタロリムス、タクロリムス、およびピメクロリムス、ならびにこれらの混合物から選択される増殖抑制剤である、請求項1〜7のいずれか一項に記載の組成物。
- 前記疎水性生理活性物質が、25℃および中性pHで100μg/mL未満の水中での溶解度を有する、請求項1〜8のいずれか一項に記載の組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261722735P | 2012-11-05 | 2012-11-05 | |
US61/722,735 | 2012-11-05 | ||
US201261740713P | 2012-12-21 | 2012-12-21 | |
US61/740,713 | 2012-12-21 | ||
PCT/US2013/068539 WO2014071387A1 (en) | 2012-11-05 | 2013-11-05 | Composition and method for delivery of hydrophobic active agents |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015535292A JP2015535292A (ja) | 2015-12-10 |
JP2015535292A5 JP2015535292A5 (ja) | 2016-12-28 |
JP6438406B2 true JP6438406B2 (ja) | 2018-12-12 |
Family
ID=49585661
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015540868A Active JP6438406B2 (ja) | 2012-11-05 | 2013-11-05 | 疎水性生理活性物質を送達するための組成物および方法 |
Country Status (5)
Country | Link |
---|---|
US (2) | US9555119B2 (ja) |
EP (1) | EP2914297B1 (ja) |
JP (1) | JP6438406B2 (ja) |
CA (1) | CA2890205C (ja) |
WO (1) | WO2014071387A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11529440B2 (en) | 2011-05-20 | 2022-12-20 | Surmodics, Inc. | Delivery of hydrophobic active agent particles |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102427834A (zh) | 2009-04-28 | 2012-04-25 | 苏尔莫迪克斯公司 | 用于递送生物活性剂的装置和方法 |
US9757497B2 (en) | 2011-05-20 | 2017-09-12 | Surmodics, Inc. | Delivery of coated hydrophobic active agent particles |
US10213529B2 (en) | 2011-05-20 | 2019-02-26 | Surmodics, Inc. | Delivery of coated hydrophobic active agent particles |
US11246963B2 (en) | 2012-11-05 | 2022-02-15 | Surmodics, Inc. | Compositions and methods for delivery of hydrophobic active agents |
US9555119B2 (en) | 2012-11-05 | 2017-01-31 | Surmodics, Inc. | Composition and method for delivery of hydrophobic active agents |
US9439892B2 (en) * | 2013-05-16 | 2016-09-13 | Surmodics, Inc. | Macrolide particulates, methods for preparation, and medical devices associated therewith |
US9682100B2 (en) | 2015-01-26 | 2017-06-20 | International Business Machines Corporation | Cationic polyamines for treatment of viruses |
ES2734394T3 (es) | 2015-03-30 | 2019-12-05 | Taris Biomedical Llc | Dispositivos para la administración local fármacos al tracto urinario superior |
US9795624B2 (en) * | 2015-05-04 | 2017-10-24 | Research Foundation Of The City University Of New York | Cationic polymers as co-drugs for chemotherapeutic agents |
US11103589B2 (en) | 2016-01-08 | 2021-08-31 | Apg Therapeutics, Inc. | Polyethylenimine (PEI)-polypeptide conjugates and methods of use thereof |
US10898446B2 (en) | 2016-12-20 | 2021-01-26 | Surmodics, Inc. | Delivery of hydrophobic active agents from hydrophilic polyether block amide copolymer surfaces |
Family Cites Families (176)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3389099A (en) | 1966-02-23 | 1968-06-18 | Koppers Co Inc | Ultraviolet light stabilizers for plastic materials |
US3936391A (en) | 1971-06-16 | 1976-02-03 | Drackett Company | Hydrated polyglycerol ester composition |
CH616337A5 (ja) | 1977-10-21 | 1980-03-31 | Schneider Medintag Ag | |
NL8103356A (nl) | 1981-07-15 | 1983-02-01 | Unilever Nv | Polyglycerolesters-bevattende vetmengsels en werkwijze ter onderdrukking van het ontstaan van triglycerideconglomeraten onder toepassing van polyglycerolesters. |
US5002582A (en) | 1982-09-29 | 1991-03-26 | Bio-Metric Systems, Inc. | Preparation of polymeric surfaces via covalently attaching polymers |
US5512329A (en) | 1982-09-29 | 1996-04-30 | Bsi Corporation | Substrate surface preparation |
US4973493A (en) | 1982-09-29 | 1990-11-27 | Bio-Metric Systems, Inc. | Method of improving the biocompatibility of solid surfaces |
US4722906A (en) | 1982-09-29 | 1988-02-02 | Bio-Metric Systems, Inc. | Binding reagents and methods |
US4490421A (en) | 1983-07-05 | 1984-12-25 | E. I. Du Pont De Nemours And Company | Balloon and manufacture thereof |
US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
DK406686D0 (da) | 1986-08-26 | 1986-08-26 | Hans Bundgaard | Carboxylsyrederivater |
US4979959A (en) | 1986-10-17 | 1990-12-25 | Bio-Metric Systems, Inc. | Biocompatible coating for solid surfaces |
US5263992A (en) | 1986-10-17 | 1993-11-23 | Bio-Metric Systems, Inc. | Biocompatible device with covalently bonded biocompatible agent |
US5041089A (en) | 1987-12-11 | 1991-08-20 | Devices For Vascular Intervention, Inc. | Vascular dilation catheter construction |
US5087246A (en) | 1988-12-29 | 1992-02-11 | C. R. Bard, Inc. | Dilation catheter with fluted balloon |
US5201753A (en) | 1989-03-17 | 1993-04-13 | Merit Medical Systems, Inc. | Totally self-contained, digitally controlled, disposable syringe inflation system, and method for monitoring, displaying and recording balloon catheter inflation data |
US5318587A (en) | 1989-08-25 | 1994-06-07 | C. R. Bard, Inc. | Pleated balloon dilatation catheter and method of use |
US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
EP0479730B1 (de) | 1990-10-04 | 1995-04-19 | Schneider (Europe) Ag | Ballondilationskatheter |
US5102402A (en) | 1991-01-04 | 1992-04-07 | Medtronic, Inc. | Releasable coatings on balloon catheters |
US5195969A (en) | 1991-04-26 | 1993-03-23 | Boston Scientific Corporation | Co-extruded medical balloons and catheter using such balloons |
CA2074304C (en) | 1991-08-02 | 1996-11-26 | Cyril J. Schweich, Jr. | Drug delivery catheter |
US6515009B1 (en) | 1991-09-27 | 2003-02-04 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5811447A (en) | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
DE4226174A1 (de) | 1992-08-07 | 1994-02-10 | Solvay Fluor & Derivate | Polyglycerinfettsäureestergemisch |
US5500180A (en) | 1992-09-30 | 1996-03-19 | C. R. Bard, Inc. | Method of making a distensible dilatation balloon using a block copolymer |
US5414075A (en) | 1992-11-06 | 1995-05-09 | Bsi Corporation | Restrained multifunctional reagent for surface modification |
US5297607A (en) | 1992-12-15 | 1994-03-29 | Pierre Beauchamp | Sheet curtain with vertical blind actuating mechanism |
US5981568A (en) | 1993-01-28 | 1999-11-09 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
US5382234A (en) | 1993-04-08 | 1995-01-17 | Scimed Life Systems, Inc. | Over-the-wire balloon catheter |
US5399371A (en) | 1993-06-17 | 1995-03-21 | Henkel Corporation | Low calorie substitute for an edible oil |
US5344402A (en) | 1993-06-30 | 1994-09-06 | Cardiovascular Dynamics, Inc. | Low profile perfusion catheter |
DK0797988T3 (da) | 1993-07-19 | 2009-05-11 | Univ British Columbia | Anti-angiogene præparater og fremgangsmåder til anvendelse deraf |
EP1118325B2 (en) | 1993-07-29 | 2010-01-06 | The United States of America, represented by the Secretary, Department of Health and Human Services | Use of Paclitaxel and its derivatives in the manufacture of a medicament for treating restenosis. |
US6896842B1 (en) | 1993-10-01 | 2005-05-24 | Boston Scientific Corporation | Medical device balloons containing thermoplastic elastomers |
US5397307A (en) | 1993-12-07 | 1995-03-14 | Schneider (Usa) Inc. | Drug delivery PTCA catheter and method for drug delivery |
WO1995022367A1 (en) | 1994-02-17 | 1995-08-24 | Scimed Life Systems, Inc. | Process improvements for preparing catheter balloons |
EP0748232B8 (en) | 1994-03-02 | 2009-03-25 | Boston Scientific Limited | Block copolymer elastomer catheter balloons |
WO1995028983A1 (en) | 1994-04-20 | 1995-11-02 | Solar Ronald J | Active perfusion dilatation catheter |
US5585506A (en) | 1994-07-22 | 1996-12-17 | Lonza Inc. | One phase production of polyglycerol esters |
US5667493A (en) | 1994-12-30 | 1997-09-16 | Janacek; Jaroslav | Dilation catheter |
US5833657A (en) | 1995-05-30 | 1998-11-10 | Ethicon, Inc. | Single-walled balloon catheter with non-linear compliance characteristic |
US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
US5714360A (en) | 1995-11-03 | 1998-02-03 | Bsi Corporation | Photoactivatable water soluble cross-linking agents containing an onium group |
WO1997017098A1 (en) | 1995-11-08 | 1997-05-15 | Scimed Life Systems, Inc. | Method of balloon formation by cold drawing/necking |
US5891451A (en) | 1996-06-25 | 1999-04-06 | Elizabeth Arden Company, Division Of Conopco, Inc. | Skin treatment with salicylic acid esters |
US5980948A (en) | 1996-08-16 | 1999-11-09 | Osteotech, Inc. | Polyetherester copolymers as drug delivery matrices |
US5728732A (en) | 1996-11-27 | 1998-03-17 | Elizabeth Arden Company, Division Of Conopco, Inc. | Skin treatment with salicylic acid esters and retinoids |
WO1998043618A2 (en) | 1997-03-31 | 1998-10-08 | Neorx Corporation | Use of cytoskeletal inhibitors for the prevention of restenosis |
JPH10328293A (ja) | 1997-06-04 | 1998-12-15 | Unitika Ltd | 医療用具及びその製造方法 |
US6121027A (en) | 1997-08-15 | 2000-09-19 | Surmodics, Inc. | Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups |
US6762019B2 (en) | 1997-09-30 | 2004-07-13 | Surmodics, Inc. | Epoxide polymer surfaces |
US6465178B2 (en) | 1997-09-30 | 2002-10-15 | Surmodics, Inc. | Target molecule attachment to surfaces |
US5858653A (en) | 1997-09-30 | 1999-01-12 | Surmodics, Inc. | Reagent and method for attaching target molecules to a surface |
US6517515B1 (en) | 1998-03-04 | 2003-02-11 | Scimed Life Systems, Inc. | Catheter having variable size guide wire lumen |
US6007833A (en) | 1998-03-19 | 1999-12-28 | Surmodics, Inc. | Crosslinkable macromers bearing initiator groups |
US7208010B2 (en) | 2000-10-16 | 2007-04-24 | Conor Medsystems, Inc. | Expandable medical device for delivery of beneficial agent |
DE19814730A1 (de) | 1998-04-02 | 1999-10-07 | Basf Ag | Verwendung von N-Vinyllacram oder N-Vinylamin haltigen Copolymeren als Matrix zur Herstellung von festen pharmazeutischen und kosmetischen Darreichungsformen |
EP1083960A4 (en) | 1998-05-15 | 2001-09-12 | Medgination Inc | DILATION SYSTEM WITH A BALLOON |
US6254634B1 (en) | 1998-06-10 | 2001-07-03 | Surmodics, Inc. | Coating compositions |
WO2000010622A1 (en) | 1998-08-20 | 2000-03-02 | Cook Incorporated | Coated implantable medical device |
US6613066B1 (en) | 1998-10-05 | 2003-09-02 | Kaneka Corporation | Balloon catheter and production method therefor |
US6340465B1 (en) | 1999-04-12 | 2002-01-22 | Edwards Lifesciences Corp. | Lubricious coatings for medical devices |
AU6762600A (en) | 1999-08-09 | 2001-03-05 | General Hospital Corporation, The | Drug-carrier complexes and methods of use thereof |
US6278018B1 (en) | 1999-12-14 | 2001-08-21 | Surmodics, Inc. | Surface coating agents |
KR100416242B1 (ko) | 1999-12-22 | 2004-01-31 | 주식회사 삼양사 | 약물전달체용 생분해성 블록 공중합체의 액체 조성물 및이의 제조방법 |
US6703040B2 (en) | 2000-01-11 | 2004-03-09 | Intralytix, Inc. | Polymer blends as biodegradable matrices for preparing biocomposites |
US6589665B2 (en) | 2000-05-30 | 2003-07-08 | Novartis Ag | Coated articles |
AU2002227308A1 (en) | 2000-11-06 | 2002-05-15 | Lonza Inc. | Processes for preparing linear polyglycerols and polyglycerol esters |
US6444324B1 (en) | 2000-12-01 | 2002-09-03 | Scimed Life Systems, Inc. | Lubricated catheter balloon |
US6623504B2 (en) | 2000-12-08 | 2003-09-23 | Scimed Life Systems, Inc. | Balloon catheter with radiopaque distal tip |
US6623452B2 (en) | 2000-12-19 | 2003-09-23 | Scimed Life Systems, Inc. | Drug delivery catheter having a highly compliant balloon with infusion holes |
US6663662B2 (en) | 2000-12-28 | 2003-12-16 | Advanced Cardiovascular Systems, Inc. | Diffusion barrier layer for implantable devices |
US7771468B2 (en) | 2001-03-16 | 2010-08-10 | Angiotech Biocoatings Corp. | Medicated stent having multi-layer polymer coating |
US7034037B2 (en) | 2001-06-29 | 2006-04-25 | Ethicon, Inc. | Compositions and medical devices utilizing bioabsorbable polymeric waxes and rapamycin |
US7456025B2 (en) | 2001-08-28 | 2008-11-25 | Porex Corporation | Sintered polymer membrane for analyte detection device |
EP1429833B1 (en) | 2001-09-28 | 2018-02-14 | Boston Scientific Limited | Catheter comprising nanocomposites |
US7438710B2 (en) | 2001-11-07 | 2008-10-21 | Anderson Kent D | Distal protection device with local drug infusion by physician to maintain patency |
AU2002365360A1 (en) * | 2001-11-28 | 2003-06-10 | Biopolymed Inc. | Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same |
US7348055B2 (en) | 2001-12-21 | 2008-03-25 | Surmodics, Inc. | Reagent and method for providing coatings on surfaces |
US7797033B2 (en) | 2002-04-08 | 2010-09-14 | Smart Pill Corporation | Method of using, and determining location of, an ingestible capsule |
US20040051201A1 (en) | 2002-04-11 | 2004-03-18 | Greenhalgh Skott E. | Coated stent and method for coating by treating an electrospun covering with heat or chemicals |
US20030195611A1 (en) | 2002-04-11 | 2003-10-16 | Greenhalgh Skott E. | Covering and method using electrospinning of very small fibers |
US20050187605A1 (en) | 2002-04-11 | 2005-08-25 | Greenhalgh Skott E. | Electrospun skin capable of controlling drug release rates and method |
US20030211135A1 (en) | 2002-04-11 | 2003-11-13 | Greenhalgh Skott E. | Stent having electrospun covering and method |
EP2851097A3 (en) | 2002-07-12 | 2015-06-10 | Cook Medical Technologies LLC | Drug-coated angioplasty balloons |
CA2495913A1 (en) * | 2002-08-23 | 2004-03-04 | Medigene Oncology Gmbh | Non-vesicular cationic lipid formulations |
US20040044404A1 (en) | 2002-08-30 | 2004-03-04 | Stucke Sean M. | Retention coatings for delivery systems |
GB0221942D0 (en) * | 2002-09-20 | 2002-10-30 | Univ Strathclyde | Drug delivery |
DE10244847A1 (de) | 2002-09-20 | 2004-04-01 | Ulrich Prof. Dr. Speck | Medizinische Vorrichtung zur Arzneimittelabgabe |
US8202530B2 (en) | 2002-09-27 | 2012-06-19 | Advanced Cardiovascular Systems, Inc. | Biocompatible coatings for stents |
CA2516986C (en) | 2003-02-26 | 2013-02-12 | Boston Scientific Limited | Balloon catheter having enhanced deliverability |
IES20030294A2 (en) | 2003-04-17 | 2004-10-20 | Medtronic Vascular Connaught | Coating for biomedical devices |
US7544381B2 (en) | 2003-09-09 | 2009-06-09 | Boston Scientific Scimed, Inc. | Lubricious coatings for medical device |
EP1521332B1 (en) | 2003-09-30 | 2007-08-15 | Lucent Technologies Network Systems GmbH | A compact multiple-band antenna arrangement |
US7309593B2 (en) | 2003-10-01 | 2007-12-18 | Surmodics, Inc. | Attachment of molecules to surfaces |
WO2005037338A1 (en) | 2003-10-14 | 2005-04-28 | Cook Incorporated | Hydrophilic coated medical device |
JP2007525146A (ja) | 2003-12-30 | 2007-09-06 | ガムリンク エー/エス | 生分解性ポリマーを含み且つ分解性を促進させたチューインガム |
EP1555278A1 (en) | 2004-01-15 | 2005-07-20 | Innocore Technologies B.V. | Biodegradable multi-block co-polymers |
US20050181015A1 (en) | 2004-02-12 | 2005-08-18 | Sheng-Ping (Samuel) Zhong | Layered silicate nanoparticles for controlled delivery of therapeutic agents from medical articles |
US8003122B2 (en) | 2004-03-31 | 2011-08-23 | Cordis Corporation | Device for local and/or regional delivery employing liquid formulations of therapeutic agents |
US8241655B2 (en) | 2004-05-12 | 2012-08-14 | Surmodics, Inc. | Coatings for medical articles including natural biodegradable polysaccharides |
US7758892B1 (en) | 2004-05-20 | 2010-07-20 | Boston Scientific Scimed, Inc. | Medical devices having multiple layers |
US20050281857A1 (en) | 2004-05-25 | 2005-12-22 | Heyer Toni M | Methods and reagents for preparing biomolecule-containing coatings |
WO2006002399A2 (en) | 2004-06-24 | 2006-01-05 | Surmodics, Inc. | Biodegradable implantable medical devices, methods and systems |
US7356368B2 (en) | 2004-07-21 | 2008-04-08 | Boston Scientific Scimed, Inc. | Light-activated anti-infective coatings and devices made thereof |
US7807750B2 (en) | 2004-08-06 | 2010-10-05 | Surmodics, Inc. | Thermally-reactive polymers |
US8119153B2 (en) | 2004-08-26 | 2012-02-21 | Boston Scientific Scimed, Inc. | Stents with drug eluting coatings |
US8173148B2 (en) | 2004-11-10 | 2012-05-08 | Tolmar Therapeutics, Inc. | Stabilized polymeric delivery system comprising a water-insoluble polymer and an organic liquid |
US20060200232A1 (en) | 2005-03-04 | 2006-09-07 | Phaneuf Matthew D | Nanofibrous materials as drug, protein, or genetic release vehicles |
CN1964750A (zh) | 2005-04-06 | 2007-05-16 | 苏莫迪克斯公司 | 用于医疗用具的生物活性的涂料组合物 |
US20060240194A1 (en) | 2005-04-26 | 2006-10-26 | Cargill, Incorporated | Polyglycerol fatty acid ester composition and coating |
US7772393B2 (en) | 2005-06-13 | 2010-08-10 | Innovative Surface Technologies, Inc. | Photochemical crosslinkers for polymer coatings and substrate tie-layer |
CN101253259A (zh) | 2005-07-20 | 2008-08-27 | 苏尔莫迪克斯公司 | 聚合物涂覆的纳米原纤结构和用于细胞维持和分化的方法 |
US8663673B2 (en) | 2005-07-29 | 2014-03-04 | Surmodics, Inc. | Devices, articles, coatings, and methods for controlled active agent release or hemocompatibility |
US20070141365A1 (en) | 2005-08-26 | 2007-06-21 | Jelle Bruce M | Silane Coating Compositions, Coating Systems, and Methods |
WO2007030302A2 (en) | 2005-09-01 | 2007-03-15 | Prescient Medical, Inc. | Drugs coated on a device to treat vulnerable plaque |
ATE540705T1 (de) | 2005-09-21 | 2012-01-15 | Surmodics Inc | Überzüge und artikel mit natürlichen biologisch abbaubaren polysacchariden |
CA2625638C (en) | 2005-11-08 | 2014-03-11 | Surmodics, Inc. | Ultra-thin photo-polymer coatings and uses thereof |
US7919108B2 (en) | 2006-03-10 | 2011-04-05 | Cook Incorporated | Taxane coatings for implantable medical devices |
WO2007084418A2 (en) | 2006-01-13 | 2007-07-26 | Surmodics, Inc. | Microparticle containing matrices for drug delivery |
US7875284B2 (en) | 2006-03-10 | 2011-01-25 | Cook Incorporated | Methods of manufacturing and modifying taxane coatings for implantable medical devices |
JP2009529967A (ja) | 2006-03-15 | 2009-08-27 | サーモディクス,インコーポレイティド | 天然生分解性ポリサッカライドの疎水性誘導体及びそれらの使用 |
US8092818B2 (en) | 2006-05-17 | 2012-01-10 | Boston Scientific Scimed, Inc. | Medical devices having bioactive surfaces |
US20080220054A1 (en) | 2006-10-13 | 2008-09-11 | Shastri V Prasad | Modulation of drug release rate from electrospun fibers |
US8414909B2 (en) | 2006-11-20 | 2013-04-09 | Lutonix, Inc. | Drug releasing coatings for medical devices |
WO2008104572A2 (en) | 2007-02-28 | 2008-09-04 | Dsm Ip Assets B.V. | Hydrophilic coating |
US8513320B2 (en) | 2007-02-28 | 2013-08-20 | Dsm Ip Assets B.V. | Hydrophilic coating |
EP2136787B1 (en) * | 2007-03-22 | 2019-08-21 | Berg LLC | Topical formulations having enhanced bioavailability |
ITTO20070356A1 (it) | 2007-05-21 | 2008-11-22 | Sorin Biomedica Cardio Srl | "composizione per il rilascio di principi attivi da dispositivi di impianto" |
KR100904207B1 (ko) * | 2007-06-01 | 2009-06-25 | (주) 태웅메디칼 | 스텐트용 약물 방출 코팅제, 그의 제조방법 및 이 코팅제로 코팅된 약물 방출 스텐트 |
US20090030504A1 (en) | 2007-07-27 | 2009-01-29 | Boston Scientific Scimed, Inc. | Medical devices comprising porous inorganic fibers for the release of therapeutic agents |
US20090043276A1 (en) | 2007-08-09 | 2009-02-12 | Boston Scientific Scimed, Inc. | Drug delivery device, compositions and methods relating thereto |
US20090043378A1 (en) | 2007-08-10 | 2009-02-12 | Medtronic Vascular, Inc. | Biocompatible Polymer System for Extended Drug Release |
US20090081276A1 (en) | 2007-08-13 | 2009-03-26 | Eben Alsberg | Bioresorbable implant composition |
WO2009076272A2 (en) | 2007-12-07 | 2009-06-18 | Boston Scientific Scimed, Inc. | Drug coated stent with endosome-disrupting conjugate |
MY160698A (en) | 2008-03-12 | 2017-03-15 | Dsm Ip Assets Bv | Hydrophilic coating |
KR20100132486A (ko) | 2008-03-12 | 2010-12-17 | 안게스 엠지 인코포레이티드 | 약제 용출형 카테터 및 그 제조방법 |
EP2257277A1 (en) * | 2008-04-04 | 2010-12-08 | MediGene AG | Solubilisation method |
JP5713897B2 (ja) | 2008-07-16 | 2015-05-07 | エボニック コーポレイションEvonik Corporation | 生理活性ペプチドを含有する微粒子を調製するためのプロセス |
US9295820B2 (en) | 2008-08-14 | 2016-03-29 | Surmodics, Inc. | Method and apparatus for coating balloon catheters |
US8049061B2 (en) | 2008-09-25 | 2011-11-01 | Abbott Cardiovascular Systems, Inc. | Expandable member formed of a fibrous matrix having hydrogel polymer for intraluminal drug delivery |
US8226603B2 (en) | 2008-09-25 | 2012-07-24 | Abbott Cardiovascular Systems Inc. | Expandable member having a covering formed of a fibrous matrix for intraluminal drug delivery |
WO2010042471A2 (en) | 2008-10-07 | 2010-04-15 | Boston Scientific Scimed, Inc. | Medical devices for delivery of therapeutic agents to body lumens |
US20100130837A1 (en) | 2008-11-25 | 2010-05-27 | The Smart Pill Corporation | Modular ingestible capsule |
CN102325805A (zh) | 2008-12-22 | 2012-01-18 | 巴斯夫欧洲公司 | 稳定聚合物的方法 |
US8685538B2 (en) * | 2009-03-25 | 2014-04-01 | Northeastern University | Stable polyelectrolyte coated nanoparticles |
BRPI1010301A2 (pt) | 2009-04-09 | 2016-03-15 | Alkermes Pharma Ireland Ltd | composição. |
CN102427834A (zh) | 2009-04-28 | 2012-04-25 | 苏尔莫迪克斯公司 | 用于递送生物活性剂的装置和方法 |
US8246576B2 (en) | 2009-05-18 | 2012-08-21 | Surmodics, Inc. | Method and apparatus for delivery of a therapeutic agent with an expandable medical device |
EP2253337A1 (en) | 2009-05-18 | 2010-11-24 | Encapson B.V. | Balloon catheter comprising pressure sensitive microcapsules. |
US10369256B2 (en) | 2009-07-10 | 2019-08-06 | Boston Scientific Scimed, Inc. | Use of nanocrystals for drug delivery from a balloon |
TW201111008A (en) | 2009-08-26 | 2011-04-01 | Univ Kyushu Nat Univ Corp | Intraluminally-indwelling medical device and process thereof |
JP5514222B2 (ja) | 2009-11-02 | 2014-06-04 | ニチバン株式会社 | 電離性放射線で架橋したヒドロゲルから成る生体内薬剤徐放用担体材料及びその製造方法 |
WO2011072199A2 (en) | 2009-12-10 | 2011-06-16 | Surmodics, Inc. | Water-soluble degradable photo-crosslinker |
RU2594729C2 (ru) | 2010-03-30 | 2016-08-20 | Сурмодикс, Инк. | Разлагаемое фотосшивающее средство |
JP5945534B2 (ja) | 2010-05-10 | 2016-07-05 | サーモディクス,インコーポレイテッド | グリセロールエステル活性剤送達システムおよび方法 |
WO2012003293A1 (en) | 2010-06-30 | 2012-01-05 | Surmodics, Inc. | Lipid coating for medical devices delivering bioactive agent |
US20120039983A1 (en) | 2010-08-11 | 2012-02-16 | Uhrich Kathryn E | Amphiphilic macromolecule-lipid complexes |
US10315987B2 (en) | 2010-12-13 | 2019-06-11 | Surmodics, Inc. | Photo-crosslinker |
CA2823355C (en) | 2010-12-30 | 2017-08-22 | Micell Technologies, Inc. | Nanoparticle and surface-modified particulate coatings, coated balloons, and methods therefore |
US20120177910A1 (en) | 2011-01-11 | 2012-07-12 | Boston Scientific Scimed, Inc. | Coated Medical Devices |
US9757497B2 (en) | 2011-05-20 | 2017-09-12 | Surmodics, Inc. | Delivery of coated hydrophobic active agent particles |
US10213529B2 (en) | 2011-05-20 | 2019-02-26 | Surmodics, Inc. | Delivery of coated hydrophobic active agent particles |
US9861727B2 (en) | 2011-05-20 | 2018-01-09 | Surmodics, Inc. | Delivery of hydrophobic active agent particles |
WO2012170706A2 (en) | 2011-06-08 | 2012-12-13 | Surmodics, Inc. | Photo-vinyl linking agents |
WO2013006947A1 (en) | 2011-07-08 | 2013-01-17 | Covalon Technologies Inc. | Method for treating a surface with a coating comprising a therapeutic agent and device with treated surface |
BR112014017675B1 (pt) | 2012-01-18 | 2021-06-22 | Surmodics, Inc | Revestimento para um dispositivo médico lubrificante com teor baixo de particulados, dispositivo médico e método de produção do mesmo |
US9410044B2 (en) | 2012-05-11 | 2016-08-09 | Surmodics, Inc. | Boron-containing linking agents |
US9631190B2 (en) | 2012-06-29 | 2017-04-25 | Surmodics, Inc. | Cell attachment coatings and methods using phosphorous-containing photoreagent |
US9555119B2 (en) | 2012-11-05 | 2017-01-31 | Surmodics, Inc. | Composition and method for delivery of hydrophobic active agents |
US11246963B2 (en) | 2012-11-05 | 2022-02-15 | Surmodics, Inc. | Compositions and methods for delivery of hydrophobic active agents |
US9629945B2 (en) | 2012-12-12 | 2017-04-25 | Surmodics, Inc. | Stilbene-based reactive compounds, polymeric matrices formed therefrom, and articles visualizable by fluorescence |
WO2014107670A1 (en) | 2013-01-04 | 2014-07-10 | Surmodics, Inc. | Low particulate lubricious coating with vinyl pyrrolidone and acidic polymer-containing layers |
CA2912690C (en) | 2013-05-16 | 2022-05-03 | Surmodics, Inc. | Compositions and methods for delivery of hydrophobic active agents |
CA2974962C (en) | 2015-01-29 | 2024-01-09 | Surmodics, Inc. | Delivery of hydrophobic active agent particles |
-
2013
- 2013-11-05 US US14/072,520 patent/US9555119B2/en active Active
- 2013-11-05 CA CA2890205A patent/CA2890205C/en active Active
- 2013-11-05 WO PCT/US2013/068539 patent/WO2014071387A1/en active Application Filing
- 2013-11-05 JP JP2015540868A patent/JP6438406B2/ja active Active
- 2013-11-05 EP EP13792207.6A patent/EP2914297B1/en active Active
-
2016
- 2016-11-21 US US15/357,496 patent/US9999675B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11529440B2 (en) | 2011-05-20 | 2022-12-20 | Surmodics, Inc. | Delivery of hydrophobic active agent particles |
Also Published As
Publication number | Publication date |
---|---|
US20170072057A1 (en) | 2017-03-16 |
US20140142166A1 (en) | 2014-05-22 |
JP2015535292A (ja) | 2015-12-10 |
CA2890205A1 (en) | 2014-05-08 |
US9555119B2 (en) | 2017-01-31 |
EP2914297A1 (en) | 2015-09-09 |
CA2890205C (en) | 2020-12-22 |
EP2914297B1 (en) | 2019-01-09 |
US9999675B2 (en) | 2018-06-19 |
WO2014071387A1 (en) | 2014-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6438406B2 (ja) | 疎水性生理活性物質を送達するための組成物および方法 | |
JP6469090B2 (ja) | 疎水性生理活性物質を送達するための組成物および方法 | |
US11246963B2 (en) | Compositions and methods for delivery of hydrophobic active agents | |
US20230190656A1 (en) | Compositions and methods relating to reduced mucoadhesion | |
US8905997B2 (en) | Therapeutic particles suitable for parenteral administration and methods of making and using same | |
JP5792729B2 (ja) | 移植可能な生体吸収性ポリマー | |
Pinelli et al. | In vivo drug delivery applications of nanogels: a review | |
JPH09510231A (ja) | 二重作用心血管剤としての酸化窒素と心血管アミンとの複合体 | |
WO2007058190A1 (ja) | 薬剤放出制御組成物および薬剤放出性医療器具 | |
JP2010519183A (ja) | 生理溶液の溶出のためのタンパク質の沈殿を用いる重合 | |
US20200030238A1 (en) | Microspheres containing therapeutic agents and related methods of use | |
US20170281914A1 (en) | Localized treatment of tissues through transcatheter delivery of active agents | |
CN105213307B (zh) | 用于粘液渗透的还原响应性靶向高分子胶束及其制备方法 | |
Vashist et al. | Chitosan Derivative and their application as Immunotherapy, Anticancer agents and in Drug delivery | |
US8246994B2 (en) | Method for delivering an active agent using a hydrogel composition | |
US20090169639A1 (en) | Particles for injection and processes for forming the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161104 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161104 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170823 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170831 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180131 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180521 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180815 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181023 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181116 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6438406 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |